Results 41 to 50 of about 3,225,994 (369)

Thyroid status modulates T lymphoma growth via cell cycle regulatory proteins and angiogenesis [PDF]

, 2014
We have shown in vitro that thyroid hormones (THs) regulate the balance between proliferation and apoptosis of T lymphoma cells. The effects of THs on tumor development have been studied, but the results are still controversial.
Barreiro Arcos, María Laura, Cayrol, Maria Florencia, Colombo, L., Cremaschi, Graciela Alicia, Díaz Flaqué, María Celeste, Klecha, Alicia Juana, Martinel Lamas, Diego José, Medina, Vanina Araceli, Paulazo, Maria Alejandra, Sterle, Helena Andrea, Valli, Eduardo   +10 more
core   +1 more source

High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC

Scientific Reports, 2023
Tumor-associated high endothelial venules (TA-HEVs) mediate lymphocyte entry into tumors. Therefore, combined anti-angiogenesis therapy and programmed death-1 (PD-1) inhibitors might stimulate tumor immunity.
Dafu Ye, Yao Jin, Yiming Weng, Xue Cui, Jinsong Wang, Min Peng, Qibin Song   +6 more
doaj   +1 more source

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. [PDF]

, 2019
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options.
Calvisi, Diego F, Che, Li, Chen, Xin, Evert, Matthias, Hu, Junjie, Liu, Xianqiong, Lu, Xinjun, Song, Xinhua, Su, Tao, Utpatel, Kirsten, Wang, Jingxiao, Wang, Pan, Xu, Meng, Zhang, Jie, Zhang, Yi   +14 more
core   +1 more source

Anti-angiogenesis in prostate cancer: knocked down but not out

Asian Journal of Andrology, 2014
Angiogenesis is a very complex physiological process, which involves multiple pathways that are dependent on the homeostatic balance between the growth factors (stimulators and inhibitors).
Marijo Bilusic, Yu-Ning Wong
doaj   +1 more source

Angiogenesis and angiogenesis inhibitors in paediatric diseases

European Journal of Pediatrics, 1992
Angiogenesis, the generation of new capillaries from existing blood vessels, is rarely observed in the healthy organism, but can present during various paediatric diseases. In this review, we describe recent progress in the understanding of pathological angiogenesis and approaches for an improved therapy of angiogenic childhood diseases.
Schweigerer, L., Fotsis, T.
openaire   +4 more sources

The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.

PLoS ONE, 2016
BackgroundCurrently, the standard treatment for newly diagnosed glioblastoma multiforme (GBM) is maximal safe surgical resection followed by radiation therapy with concurrent and adjuvant temozolomide.
Yawei Wang, Dan Xing, Meng Zhao, Jie Wang, Yang Yang   +4 more
doaj   +1 more source

The metastasis inducer CCN1 (CYR61) activates the fatty acid synthase (FASN)-driven lipogenic phenotype in breast cancer cells [PDF]

, 2016
The angiogenic inducer CCN1 (Cysteine-rich 61, CYR61) is differentially activated in metastatic breast carcinomas. However, little is known about the precise mechanisms that underlie the pro-metastatic actions of CCN1. Here, we investigated the impact of
Espinoza, Ingrid, Lupu, Ruth, Menendez, Javier A., Vellón, Luciano   +3 more
core   +1 more source

Endogenous Matrix-Derived Inhibitors of Angiogenesis

Pharmaceuticals, 2010
Endogenous inhibitors of angiogenesis are proteins or fragments of proteins that are formed in the body, which can inhibit the angiogenic process. These molecules can be found both in the circulation and sequestered in the extracellular matrix (ECM ...
Hans Petter Eikesdal, Malin Sund, Pia Nyberg   +2 more
doaj   +1 more source

Metabolism within the tumor microenvironment and its implication on cancer progression: an ongoing therapeutic target [PDF]

, 2018
Since reprogramming energy metabolism is considered a new hallmark of cancer, tumor metabolism is again in the spotlight of cancer research. Many studies have been carried out and many possible therapies have been developed in the last years.
Abdel-Aziz, Ahmadzadeh, Al-Zhoughbi, Albina, Alkan, Allard, Allen, Altman, Alves-Filho, Amelio, Araújo, Argilés, Arora, Arts, Aslanian, Astaldi, Attieh, Augsten, Auvinen, Babbar, Baker, Balasubramanian, Baltazar, Bauer, Bello-Fernandez, Beloribi-Djefaflia, Berchner-Pfannschmidt, Berge, Berrone, Birendra, Bloch-Frankenthal, Bock, Bock, Bonuccelli, Boros, Boudreau, Boukalova, Britten, Brooks, Broome, Bueno, Buqué, Burnet, Cadamuro, Cahlin, Cantelmo, Cao, Carito, Carmeliet, Carmeliet, Caro, Carrascosa, Casazza, Caspani, Catane, Cavalcante, Chakravarty, Chakravarty, Chakravarty, Chang, Chang, Chang, Chappell, Chaudhary, Chen, Chen, Chen, Chiarini, Chittezhath, Choi, Choi, Clark, Clem, Clem, Cohen, Colegio, Collins, Commisso, Covarrubias, Covarrubias, Dang, Dang, Das, Dasgupta, Daurkin, DeBerardinis, DeBerardinis, Delgoffe, Delgoffe, Dell’ Antone, Desai, DiNapoli, Dirat, Dobrina, Doherty, Dong, Draoui, Dufour, Eason, Eelen, El Sayed, Elia, Elwood, Eminel, Fallarino, Farabegoli, Farber, Feun, Fields, Figueras, Filipp, Fischer, Flaig, Flint, Floor, Floridi, Folkman, Folkman, Franklin, Gacche, Ganeshan, Garber, García-Caballero, García-Faroldi, García-Faroldi, Gatenby, Gazi, Geiger, Gentric, Gerner, Gershtein, Ghashghaeinia, Gonen, Goveia, Granchi, Grieninger, Grivennikov, Gross, Gunnink, Guo, Guo, Guppy, Guth, Halestrap, Han, Hanahan, Hanahan, Hanai, Harjes, Harjes, Haskell, Hatzivassiliou, Hayakawa, Hessini, Hitosugi, Ho, Ho, Hoff, Holm, Hosono, Huang, Hubler, Hui, Häusler, Hée, Ignatenko, Ioannesyants, Ip, Jiménez-Valerio, Jiménez-Valerio, Jochems, Johansen, Jones, Kabat, Kafkewitz, Kamphorst, Kamphorst, Kamphorst, Kannan, Karpel-Massler, Katt, Kawasaki, Kelly, Kim, Klimp, Ko, Koliaraki, Kouidhi, Koukourakis, Kridel, Krishna, Kroemer, Krützfeldt, Kubatka, Kucharzewska, la Cueva, Labow, Laing, Lampropoulou, Le, Lechowski, Lee, Lee, Leek, Leighton, Leopold, LePage, Lerma Barbaro, Li, Lin, Liu, Liu, Liu, Liu, Liu, Liu, Liu, Lopes-Coelho, Lu, Lucca, Lukey, Lunt, Luo, López-Lázaro, Löb, Ma, Madaan, Maity, Marchiq, Martinez-Outschoorn, Martinez-Outschoorn, Maráz, Mashima, Masri, Matusewicz, McCann, McKee, McLaughlin, Medina, Medina, Merchan, Meyer, Mider, Missiaen, Mitra, Mockler, Moreno-Sánchez, Morrison, Mu, Murray-Stewart, Márquez, Márquez, Nacev, Nancolas, Newsholme, Nieman, Nisoli, Noman, Norrby, Noy, Nurjhan, Nyberg, Ocaña, Ohmura, Oka, Opitz, Orimo, Pallangyo, Palm, Panda, Papandreou, Parra-Bonilla, Parry, Pascual, Pasquier, Patsoukis, Pavlides, Pavlova, Pelicano, Pellerin, Pennisi, Penny, Peters, Pisarsky, Pizer, Polanski, Polet, Pollard, Polyak, Possemato, Potente, Potente, Prager, Prager, Pushkina, Pérez-Escuredo, Quatromoni, Quesada, Quesada, Rabold, Ramjiawan, Rashid, Rattigan, Reihill, Reitzer, Ribatti, Ribatti, Ribeiro, Richard, Rider, Roberts, Rodríguez-González, Rodríguez-Prados, Rohle, Romero, Romero-García, Roy, Roy, Ruan, Ruiz-Pérez, Russell, Ryu, Saez, Salimian Rizi, Salimian Rizi, Samal, Samudio, Santos, Sanuphan, Sasaki, Saulnier Sholler, Scherz-Shouval, Schoors, Schulze, Segura, Sekar, Selak, Seltzer, Serafini, Shapot, Shapot, Shapot, Sharkia, Shime, Shin, Shurbaji, Sieber, Siu, Skelton, Song, Sonveaux, Sonveaux, Souba, Sousa, Spahr, Spinelli, Spolarics, Stacpoole, Stern, Stuart, Stumvoll, Su, Sukumar, Sánchez-López, Tachibana, Takigawa, Talekar, Tanese, Tang, Tannahill, Tebbe, Thomas, Thomas, Thornburg, Tisdale, Torosian, Torres, Trudeau, Ullah, Uray, Urdiales, Vander Heiden, Vander Heiden, Varricchi, Vasudevan, Velaei, Vera, Vornovitskaya, Végran, Wagner, Wakil, Wang, Wang, Wang, Wang, Warburg, Warburg, Wen, Whitaker-Menezes, Williams-Ashman, Wilson, Wood, Woodward, Woster, Wu, Wu, Xie, Yamanishi, Yang, Yang, Yau, Yen, Yoshida, Yoshizaki, Yu, Yuan, Yuan, Yuan, Yun, Zabala-Letona, Zahalka, Zhan, Zhang, Zhang, Zhang, Zhang, Zhang, Zhao, Zheng, Zhou, Zhu, Ziegler   +431 more
core   +2 more sources

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors

Theranostics, 2017
Resistance mechanisms against antiangiogenic drugs are unclear. Here, we correlated the antitumor and antivascular properties of five different antiangiogenic receptor tyrosine kinase inhibitors (RTKIs) (motesanib, pazopanib, sorafenib, sunitinib ...
Szilvia Torok, M. Rezeli, O. Kelemen, Á. Végvári, Kenichi Watanabe, Y. Sugihara, A. Tisza, Timea Marton, I. Kovács, J. Tóvári, V. Laszlo, T. Helbich, B. Hegedűs, T. Klikovits, M. Hoda, W. Klepetko, S. Paku, G. Marko‐Varga, B. Dome   +18 more
semanticscholar   +1 more source